康芝藥業(300086.SZ):銷售以代理為主,自營佔比較低
格隆匯11月30日丨康芝藥業(300086.SZ)於2023年11月29日接受特定對象調研,就“請拆分一下目前兒童藥和成人藥中自營和代理的收入比例、增速以及毛利率”,公司回覆稱,公司銷售以代理為主,自營佔比較低。2023年半年度,公司兒童藥營業收入為2.28億元,毛利率59.13%,營業收入比上年同期增加75.30%,毛利率比上年同期增加14.66%;成人藥營業收入5568.64萬元,毛利率49.17%,營業收入比上年同期增加8.76%,毛利率比上年同期減少14.17%;公司兒童藥的銷售收入是成人藥銷售收入的4倍左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.